Pharmacotherapy of obesity: Currently marketed and upcoming agents

American Journal of Cardiovascular Drugs

Volumn 2, Issue 4, 2002, Pages 245-253

  Bays, Harold ^a   Dujovne, Carlos ^b  

^a LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER   (United States)

^b Kansas Foundation for Clinical Pharmacology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMFEPRAMONE; ANTIOBESITY AGENT; BENZPHETAMINE; CAFFEINE; CANNABINOID RECEPTOR ANTAGONIST; CILIARY NEUROTROPHIC FACTOR; DEXAMPHETAMINE; DEXFENFLURAMINE; DOPAMINE 1 RECEPTOR BLOCKING AGENT; DOPAMINE UPTAKE INHIBITOR; ECOPIPAM; EPHEDRINE; FLUOXETINE; MAZINDOL; MULTIVITAMIN; NEUROPEPTIDE Y RECEPTOR ANTAGONIST; NORADRENALIN UPTAKE INHIBITOR; PHENDIMETRAZINE; PHENTERMINE; PHENYLPROPANOLAMINE; PROTEIN P57; RIMONABANT; RISPERIDONE; SEROTONIN 2C AGONIST; SERTRALINE; SIBUTRAMINE; TETRAHYDROLIPSTATIN; TOPIRAMATE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANOREXIA; ARTICLE; CARDIOTOXICITY; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIETARY INTAKE; DISEASE EXACERBATION; DRUG APPROVAL; DRUG EFFICACY; DRUG TOLERABILITY; DYSLIPIDEMIA; EXERCISE; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL TOXICITY; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; INSOMNIA; LIFESTYLE; LOW FAT DIET; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; PUBLIC HEALTH; RISK FACTOR; SATIETY; STROKE; TREMOR; WEIGHT REDUCTION; XEROSTOMIA;

EID: 0036382146     PISSN: 11753277     EISSN: None     Source Type: Journal    
DOI: 10.2165/00129784-200202040-00004     Document Type: Article

References (56)

1. World Health Organization. Obesity: preventing and managing the global epidemic. Report of a WHO Consultation on Obesity; 1997 Jun 3-5; Geneva. Geneva: World Health Organization, 1998
2. Mokdad AH. Serdula MK, Dietz WH, et al. The spread of the obesity epidemic in the United States. JAMA 1999; 282: 1519-22
3. Must A, Spadano J, Coakley EH, et al. The disease burden associated with overweight and obesity. JAMA 1999; 282: 1523-9
4. Patel MR, McGuire DK. Pounds of prevention: obesity therapy. Am Heart J 2001; 142: 388-90
5. Klein S. Medical management of obesity. Surg Clin North Am 2001 Oct 1; 81 (5): 1025-38
6. Berke EM, Morden NE. Medical management of obesity. Am Fam Physician 2000 Jul; 62 (2): 419-26
7. Prevalence of overweight and obesity among adults: United States. International Obesity TaskForce [onlinel. Available from URL: http://www.iotf.org/ [Accessed 2002 May 20]
8. National Center for Chronic Disease Prevention and Health Promotion [online]. Available from URL: http://www.cdc.gov/nccdphp/dnpa/obesity [Accessed 2002 May 13]
9. Lyznicki M, Young DC, Riggs JA, et al. Obesity: assessment and management in primary care. Am Family Physician 2001 Jun 1; 63 (11): 2185-96
10. Kral JG. Morbidity of severe obesity. Surg Clin North Am 2001 Oct; 81 (5): 1039-61
11. Allison DB, Fontaine KR, Manson JE, et al. Annual deaths attributable to obesity in the United States. JAMA 1999; 282: 1530-8
12. Gumbiner B. The treatment of obesity in type 2 diabetes mellitus. Prim Care 1999 Dec; 26 (4): 869-83
13. Poston WC, Foreyt JP. Successful management of the obese patient. Am Fam Physician 2000 Jun 15; 61 (12): 3615-22
14. Massie BM. Obesity and and heart failure - risk factor or mechanism? N Engl J Med 2002; 347 (5): 358-9
15. National Heart, Blood, and Lung Institute. Third Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) [online]. Available from URL: http://www.nhibi.nih.gov/guidelines/cholesterol/index.htm [Accessed 2002 May 20]
16. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults. JAMA 2002; 287: 356-9
17. Dickerson LM, Carek PJ. Drug therapy for obesity. Am Fam Physician 2000 Apr 1; 61 (7): 2131-8
18. Stone NJ, Kushner R. Effects of dietary modification and treatment of obesity. Med Clin North Am 2000 Jan; 84 (1): 95-122
19. Hensrud DD. Pharmacotherapy for obesity. Med Clin North Am 2000 Mar; 84 (2): 463-76
20. Yanovski SZ, Yanovski JA. Obesity. N Engl J Med 2002; 346: 8: 591-602
21. Lustig RH. The neuroendocrinology of obesity. Endocrinol Metab Clin North Am 2001 Sep: 30 (3): 765-85
22. Wirth A, Krause J. Long-term weight loss with sibutramine. JAMA 2001: 286: 1331-9
23. James WP, Astrup A, Finer N, et al. Effect of sibutramine on weight maintenance after weight loss: a randomized trial. Lancet 2000; 356: 2119-25
24. Dujovne CA, Zavoral JH, Rowe E, et al. Effects of sibutramine on body weight and serum lipids. Am Heart J 2001 Sep; 142 (3): 489-97
25. Lean MEJ. Sibutramine: a review of clinical efficacy. Int J Obes Relat Metab Disord 1997; 21 Suppl. 1: S30-6; discussion 37-9
26. Davidson M, Hauptman J, DiGiroloamo M, et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat. JAMA 1999; 281: 235-42
27. Sjostrom L, Rissanen A, Andersen T, et al. Randomized placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet 1998; 352: 167-72
28. Mittendorfer B, Ostlund R. Patterson BW. et al. Orlistat inhibits daily cholesterol absorption. Obes Res 2001; 9 (10): 599-604
29. Heymsfield SB, Segal KR, Hauptman J, et al. Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults. Arch Intern Med 2000 May 8; 160 (9): 1321-6
30. Lindgarde F. The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: The Swedish Multimorbidity Study. J Intern Med 2000 Sep 1; 248 (3): 245-54
31. Rossner S. Sjostrom L, Noack R, et al. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity: European Orlistat Obesity Study Group. Obes Res 2000 Jan 1; 8 (1): 49-61
32. Wadden TA, Foster GD. Behavioral treatment of obesity. Med Clin North Am 2000 Mar; 84 (2): 441-61
33. Sharpe P, Smith G. Cannabis: time for scientific evaluation of this ancient remedy? Aneth Analg 2000 Feb; 90 (2): 237-40
34. Sanofi-Synthelabo [online]. Available from URL: http://en.sanofi-synthelabo.com/ [Accessed 2002 May 20]
35. Regeneron Pharmaceuticals [online]. Available from URL: http//www.regeneron.com [Accessed 2002 May 20]
36. Durst R, Rubin-Jabotinsky K, Raskin S, et al. Risperidone in Prader-Willi syndrome [letter]. J Am Acad Child Adolesc Psychiatry 2000 May; 39 (5): 545-6
37. Rothman RB, Baumann MH, Savage JE, et al. Evidence for possible involvement of 5-HT (213) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation 2000 Dec 5; 102 (23): 2836-41
38. Fitzgerald LW, Burn TC, Brown BS, et al. Possible role of valvular serotonin 5-HT (2B) receptors in the cardiopathy associated with fenfluramine. Mol Pharmacol 2000 Jan 01; 57 (1): 75-81
39. Shapira NA. Treatment of binge-eating disorder with topiramate: a clinical case series. J Clin Psychiatry 2000 May 1; 61 (5): 368-72
40. Fruebis J. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci U S A 2001 Feb 13; 98 (4): 2005-10
41. Lebon V, Dufour S, Petersen KF, et al. Effect of triiodothyronine on mitochondrial energy coupling in human skeletal muscle. J Clin Invest 2001 Sep; 108: 733-7
42. Heymsfield SB, Greenberg AS, Fujioka D, et al. Recombinant leptin for weight loss in obese and lean adults. JAMA 1999; 282: 1568-75
43. Pi-Sunyer FX, Laferrere B, Aronne LJ, et al. Obesity: a modern day epidemic. J Clin Endocrinol Metab 1999 Jan 1; 84 (1): 3-12
44. Ahren B, Holst JJ, Efendic S. Andidiabetogenic action of cholecystokinin-8 in type 2 diabetes. J Clin Endocrinol Metab 2000 Mar; 85 (3): 1043-8
45. Verdich C, Flint A, Gutzwiller JP, et al. A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans. J Clin Endocrinol Metab 2001 Sep; 86 (9): 4382-9
46. Zander M. Madsbad S, Madsen JL, et al. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 2002 Mar 9; 359 (9309): 824-30
47. Bertin E, Arner P, Bolinder J, et al. Action of glucagon and glucagon-like peptide-1-(7-36) amide on lipolysis in human subcutaneous adipose tissue and skeletal muscle in vivo. J Clin Endocrinol Metab 2001 Mar; 86 (3): 1229-34
48. Myers SE, Carrel AL, Whitman BY, et al. Sustained benefit after 2 years of growth hormone on body composition, fat utilization, physical strength, and agility and growth in Prader-Willi syndrome. J Pediatr 2000 Jul; 137 (1): 43-9
49. Smith SR, Jonge DL, Pellymounter M, et al. Peripheral administration of human corticotropin-releasing hormone: a novel method to increase energy expenditure and fat oxidation in man. J Clin Endocrinol Metab 2001 May; 86 (5): 1991-8
50. The North American Association for the Study of Obesity [online]. Available from URL: http://www.naaso.org [Accessed 2002 June 5]
51. National Heart, Lung, and Blood Institute. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults [online]. Available from URL: http://www.nhlbi.nih.gov/guidelines/obesity [Accessed 2002 May 20]
52. Wadden TA. Effects of sibutramine plus orlistat in obese women following 1 year of treatment by sibutramine alone, a placebo-controlled trial. Obes Res 2000 Sep 1; 8 (6): 431-7
53. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus: The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993; 329: 977-86
54. Turner R, Cull C, Holman R. United Kingdom Prospective Diabetes Study 17: a 9-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus. Ann Intern Med 1996; 124 (1 Pt 2): 136-45
55. Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 1986; 8: 1245-55
56. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994 Nov 19; 344 (8934): 1383-9